Inventor
STASI LUIGI PIERO
IT24 patents
⚠️ This page may combine multiple inventors who share the name “STASI LUIGI PIERO”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
NUEVOLUTION AS
8 patentsUS10689383B2Jun 23, 2020
Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
NUEVOLUTION AS6 citations81
US10683293B2Jun 16, 2020
Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
NUEVOLUTION AS3 citations70
US11254681B2Feb 22, 2022
Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
NUEVOLUTION AS1 citations60
US12441704B2Oct 14, 2025
Compounds active towards nuclear receptors
NUEVOLUTION AS0 citations56
US11685727B2Jun 27, 2023
Compounds active towards nuclear receptors
NUEVOLUTION AS0 citations56
US11613532B2Mar 28, 2023
Compounds active towards nuclear receptors
NUEVOLUTION AS0 citations50
US11780843B2Oct 10, 2023
Compounds active towards nuclear receptors
NUEVOLUTION AS0 citations49
US11447479B2Sep 20, 2022
Compounds active towards nuclear receptors
NUEVOLUTION AS0 citations48
GLAXOSMITHKLINE IP DEV LTD
4 patentsUS9815841B2Nov 14, 2017
Compounds
GLAXOSMITHKLINE IP DEV LTD2 citations69
US10975081B2Apr 13, 2021
Substituted fused pyrazole compounds and their use as LRRK2 inhibitors
GLAXOSMITHKLINE IP DEV LTD1 citations61
US10618901B2Apr 14, 2020
LRRK2 inhibitors for the treatment of Parkinson's disease
GLAXOSMITHKLINE IP DEV LTD1 citations60
US10087186B2Oct 2, 2018
Compounds as LRRK2 kinase inhibitors
GLAXOSMITHKLINE IP DEV LTD1 citations50
Rottapharm Biotech Srl
4 patentsUS9174977B2Nov 3, 2015
2-azabicyclo[4.1.0]heptane derivatives as orexin receptor antagonists for the treatment of certain disorders
Rottapharm Biotech Srl0 citations51
US9498478B2Nov 22, 2016
Spiro aminic compounds with NK1 antagonist activity
Rottapharm Biotech Srl0 citations50
US9493438B2Nov 15, 2016
4,4-difluoro-piperidine-compounds
Rottapharm Biotech Srl0 citations35
US9062033B2Jun 23, 2015
Chemical compounds
Rottapharm Biotech Srl0 citations35
GLAXO GROUP LTD
3 patentsUS7459456B2Dec 2, 2008
Quinoline and quinazoline derivatives having affinity for 5HT1-type receptors
GLAXO GROUP LTD7 citations69
US7592346B2Sep 22, 2009
Quinoline and quinazoline derivatives having affinity for 5HT1-type receptors
GLAXO GROUP LTD1 citations59
US7732600B2Jun 8, 2010
Quinoline and quinazoline derivatives having affinity for 5HT1-type receptors
GLAXO GROUP LTD0 citations49
BORRIELLO MANUELA
3 patentsUS8828987B2Sep 9, 2014
Pyridine amide derivatives as EP4 receptor antagonists
BORRIELLO MANUELA4 citations65
US9120824B2Sep 1, 2015
Cyclic amine derivatives as EP4 receptor agonists
BORRIELLO MANUELA1 citations45
US9181279B2Nov 10, 2015
Cyclic amine derivatives as EP4 receptor antagonists
BORRIELLO MANUELA0 citations34